[In vitro antibacterial effect of a new oral cephalosporin, cefixime. Results of a multicenter study].
Minimal inhibitory concentrations (MIC) of cefixime (CXM) were evaluated by agar dilution against 2,469 bacterial strains isolated in 10 hospitals. For Enterobacteriaceae, MIC 50 and 90% micrograms/ml were respectively: (I) naturally non beta lactamase producing species: E. coli and Shigella 0.25-0.5; Salmonella 0.06-0.25; P. mirabilis 0.008-0.032. (II) chromosomal penicillinase producing species: Klebsiella 0.06-2. (III) chromosomal cephalosporinase producing species: E. cloacae and C. freundii 1-greater than 128; S. marcescens 0.25-16; indole + Proteus 0.06-4; P. stuartii 0.032-0.5. Activity of CXM was not modified against plasmid-mediated penicillinase producing strains, but CXM was inactive on cephalosporinase hyperproducing strains and on broad spectrum beta lactamases producing strains. CXM was inactive on P. aeruginosa (MIC 50 and 90%: 64-128) and on A. baumannii (16-128). Haemophilus and Gonococci, regardless of beta-lactamase production status, and Meningococci were very susceptible to CXM (MIC 0.008-0.12). B. catarrhalis was generally inhibited by 0.03 to 0.5. CXM was poorly active on methicillin susceptible Staphylococci (MIC 50 and 90%: 1-64) and inactive on methicillin resistant strains. Enterococci were generally resistant whereas Streptococci and Pneumococci were inhibited by low concentrations: 0.008 to 1. These antibacterial properties place CXM in excellent position among oral cephalosporins.
Soussy
C J
CJ
Service de Bactériologie, Centre Hospitalier Universitaire Henri Mondor, Creteil.
Kitzis
M D
MD
Thabaut
A
A
Chanal
M
M
Bure
A
A
Vergnaud
M
M
Reynaud
A E
AE
Coulet
M
M
Dabernat
H
H
Muller-Serieys
C
C
D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D005779:Immunodiffusion; D008826:Microbial Sensitivity Tests; D015337:Multicenter Studies as Topic
D020682:Cefixime; D002439:Cefotaxime
Activité antibactérienne in vitro d'une nouvelle céphalosporine orale, le céfixime. Résultats d'une étude multicentrique.